Inloggen

Login
 
Wachtwoord vergeten?

Week 12 - Release Annual Report 2014

Volgen
 
Klik hier om dit forumtopic te volgen en automatisch op de hoogte gehouden te worden bij nieuwe berichten.
634 Posts, Pagina: « 1 2 3 4 5 6 ... 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 » | Laatste
Aantal posts per pagina:  20 50 100 | Omlaag ↓
Beur
0
quote:

lower schreef op 19 mrt 2015 om 09:39:


[...]

Ik bedoelde de stijging afgelopen dagen, 'ajb nieuwe commissarissen voor jullie ook een paar pakketjes met aandelen'
Ok! :)
1 2 3
0
quote:

dmem2 schreef op 19 mrt 2015 om 09:57:


het valt nou nooit eens echt mee bij Pharming.


gaat al jaren zo ......... speelbal is het ..
DickMat
0
Kan die slijmen nou nooit met een positieve toelichting komen zodat er weer vertrouwen komt. Wel weer 2 opvreters toevoegen
Pharmking
0
quote:

super imtec schreef op 19 mrt 2015 om 10:00:


het is 10 uur en heb ze nog steeds



je kunt nu wel goedkoop inslaan....;-)
Pharmking
0
quote:

patrick 22 schreef op 19 mrt 2015 om 10:05:


0,376 -0,009 (-2,34%) 10:03 dump van 1 miljoen stukjes tja


en dan vallen een aantal stoplossjes weg....
nu ff betijen en dan weer up!
[verwijderd]
1
quote:

DickMat schreef op 19 mrt 2015 om 10:03:


Kan die slijmen nou nooit met een positieve toelichting komen zodat er weer vertrouwen komt. Wel weer 2 opvreters toevoegen


Nou... Hier mag je best vrolijk van worden hoor... :-)



CEO’S STATEMENT


For Pharming, 2014 was a long-awaited year of
important transitions:


After starting the year with a significant positive
correction in valuation, the Company was able to solidify
its balance sheet by means of a private equity
placement in April that yielded net proceeds of €14.0
million.
In July, the FDA approved Ruconest for acute attacks of
angioedema in patients with Hereditary Angioedema
(HAE). The approval is a major milestone for Pharming.
Until now, there has not been an FDA approved
recombinant C1 esterase inhibitor option to treat
symptoms of HAE.


For many years we have strived to make Ruconest available to the HAE patient community in the US, because we
are aware of the great value and benefit this product adds to patients’ lives. The unpredictability of HAE can make
patients feel uncertain about when their next attack might strike, which is why it is important to have a medicine that
can be administered by the patient themselves. The US market for acute and prophylaxis HAE continued to expand
during 2014 and is now estimated at almost US$1 billion.
Ruconest was subsequently launched by US commercialisation partner Salix Pharmaceuticals, in November. In the
same month the receipt of a US$20.0 million milestone payment was triggered from Salix for the first commercial sale
of Ruconest in the US.


In September, the Company acquired certain assets from TRM SASU for €0.5 million in cash, including product leads
for the development of Enzyme Replacement Therapies (ERT) for Pompe, Fabry’s and Gaucher’s disease and Factor
VIII for the treatment of Haemophilia A. To facilitate optimisation of these products and to broaden the pipeline
beyond the Ruconest franchise, we have set up an in-house Paris-based research group for the creation of new
product leads from our biologics technology platform and for the subsequent development of the product leads to
approvable products. This will be done either through the strategic collaboration with SIPI for products of mutual
interest to SIPI and Pharming, such as Factor VIII for Haemophilia A or through Pharming’s in-house new product
development group (NPD), based in Boston. The NPD group was initiated early in 2015. Dr. Perry Calias, our newly
appointed Chief Scientific Officer (CSO), will have overall responsibility for the development of these ERT
programmes and will be based in Boston.


In October, we announced the initiation of direct commercialisation of Ruconest in Austria, Germany and the
Netherlands. We have hired a small European team of experienced HAE commercialisation and medical affairs
specialists to lead the direct commercialisation activities in these countries. This step forward into direct
commercialisation of Ruconest became possible as result of our improved balance sheet and opens up new
opportunities for Pharming to not only grow revenues, but also, as those revenues build, to put in place the right size
of specialist commercial infrastructure which could, over time, be leveraged through the marketing of other products.
Another potential driver of such transition is the ongoing Phase II study for Ruconest in the additional indication of
prophylaxis of HAE. This study is the first step of a 50/50 shared cost development programme with our US partner
Salix. The study was started in September and is being conducted at sites in Europe and the United States.

The first patient was enrolled in early January 2015, patient enrollment for the study continues. Pharming and Salix
will equally share the development costs for Ruconest for HAE prophylaxis and Pharming will receive an undisclosed
milestone payment from Salix at FDA approval for this additional indication.
All of this means that we have now established a platform from which we can confidently build a financially
sustainable enterprise with a pipeline beyond the Ruconest franchise.
To effectuate the transition into a financially sustainable enterprise we depend on revenues from Ruconest sales
from:
? Salix launched Ruconest in November 2014 in the US. Ruconest is made available to eligible HAE patients in the
US under a full service patient support programme; Ruconest Solutions.
? Swedish Orphan Biovitrum AB (Sobi) continues to be the distributor for the EU countries and former CIS
countries.
? Pharming’s direct commercialisation activities in Austria, Germany and the Netherlands. Early 2015, Pharming
developed RucoVitae™; a full service support programme for the treatment of acute attacks of HAE with
Ruconest for eligible HAE patients in Austria, Germany and the Netherlands.
? MegaPharm Ltd. launched Ruconest during the 2nd
half of 2014 in Israel.
As a result of our achievements in 2014 and the ongoing development projects, we look forward with confidence to an
exciting 2015, with potentially significant value-inflexion points and again increasing Ruconest sales, both from our
partners and as a result of our own commercialisation activities.
I would like to thank all of our employees, investors and partners for their ongoing commitment and support during
2014 and for keeping faith in Pharming’s potential to be unlocked. I look forward to the continued delivery on our
challenging objectives during what promises to be yet another very busy year in the continuing transition of Pharming.

Leiden, 18 March 2015

Sijmen de Vries
Chief Executive Officer and Chairman o
't zal maar gebeuren
0
quote:

DickMat schreef op 19 mrt 2015 om 10:03:


Kan die slijmen nou nooit met een positieve toelichting komen zodat er weer vertrouwen komt. Wel weer 2 opvreters toevoegen

maar goed dat geen van beiden prins van oranje is.:-)
[verwijderd]
0
Als de grote happer deze namiddag niet opnieuw aangaat ... 50% er uit (met winst over 0,36)
twopence
0
quote:

't zal maar gebeuren schreef op 19 mrt 2015 om 10:14:


[...]
maar goed dat geen van beiden prins van oranje is.:-)


Ik denk dat je hiermee naar Antonov verwijst.
Beleg klein
0
Ik kwam onderstaand advies tegen
Bank Advies Potentieel Doel Datum
KBC Securities Hold 17,00 0,40 05/03/15

Weet iemand wat de bedoeling is met de term potentieel maar daaronder 17,00
Wat houdt die 17,00 in ??
634 Posts, Pagina: « 1 2 3 4 5 6 ... 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Pharming Group Meer »

Koers 1,251   Verschil -0,02 (-1,42%)
Laag 1,247   Volume 9.467.978
Hoog 1,276   Gem. Volume 6.603.320
11-nov-19 17:35
label premium

Mooie winst op Pharming

Het laatste advies leest u als IEX Premium-lid

Inloggen Ontdek Premium